Martires Kathryn J, Ra Seong, Abdulla Farah, Cassarino David S
*Department of Dermatology, New York University School of Medicine, New York, NY; †Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; ‡San Diego Pathologists Medical Group, Los Angeles, CA; §Department of Dermatology, University of Chicago Pritzker School of Medicine; and ¶Department of Pathology, Southern California Permanente Medical Group, Sunset Medical Center, Los Angeles, CA.
Am J Dermatopathol. 2015 Nov;37(11):822-33. doi: 10.1097/DAD.0000000000000375.
CD30 primary cutaneous lymphoproliferative diseases include both lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (PCALCL). The neoplastic cell of most primary CD30 lymphoproliferative disorders is CD4 positive. The terminology LyP "type D" has been used to describe a growing number of cases of LyP with a predominantly CD8 infiltrate. PCALCL with a CD8 phenotype has also been described, which presents a particularly difficult diagnostic and management challenge, given the difficulty in distinguishing it histologically from other cytotoxic lymphomas such as primary cutaneous aggressive epidermotropic CD8 cytotoxic T-cell lymphoma and CD8 gamma/delta and natural killer/T-cell lymphoma. We report 7 additional cases of these rare cutaneous CD8/CD30 lymphoproliferative disorders. We also present a unique case of CD8/CD30 LyP with histologic similarities to LyP type B. In all 7 of our cases of CD8 LyP and CD8 anaplastic large cell lymphoma, we found focal to diffuse MUM-1 positivity. We propose that MUM-1 may represent an adjunctive marker for CD8 lymphoproliferative disease. Finally, we review the current literature on cases of CD8 LyP and PCALCL. For the 106 cases examined, we found similar clinical and histologic features to those reported for traditional CD4CD30 LyP and PCALCL.
CD30原发性皮肤淋巴增殖性疾病包括淋巴瘤样丘疹病(LyP)和原发性皮肤间变性大细胞淋巴瘤(PCALCL)。大多数原发性CD30淋巴增殖性疾病的肿瘤细胞为CD4阳性。术语“D型”LyP已被用于描述越来越多以CD8浸润为主的LyP病例。也有关于具有CD8表型的PCALCL的描述,鉴于其在组织学上难以与其他细胞毒性淋巴瘤(如原发性皮肤侵袭性亲表皮性CD8细胞毒性T细胞淋巴瘤以及CD8γ/δ和自然杀伤/T细胞淋巴瘤)相区分,这带来了特别困难的诊断和管理挑战。我们报告了另外7例这些罕见的皮肤CD8/CD30淋巴增殖性疾病病例。我们还展示了1例与B型LyP具有组织学相似性的CD8/CD30 LyP独特病例。在我们所有7例CD8 LyP和CD8间变性大细胞淋巴瘤病例中,我们发现灶性至弥漫性MUM-1阳性。我们提出MUM-1可能代表CD8淋巴增殖性疾病的辅助标志物。最后,我们回顾了关于CD8 LyP和PCALCL病例的当前文献。对于所检查的106例病例,我们发现其临床和组织学特征与传统的CD4+CD30+LyP和PCALCL所报告的特征相似。